A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma
Clinical trial NCT03463681 · COMPLETED
Trial details
- NCT number
- NCT03463681
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-11
- Primary completion
- 2021-04-08
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.